Edition:
India

MorphoSys AG (MORG.DE)

MORG.DE on Xetra

109.90EUR
4:07pm IST
Change (% chg)

€1.00 (+0.92%)
Prev Close
€108.90
Open
€110.50
Day's High
€110.50
Day's Low
€109.10
Volume
28,296
Avg. Vol
151,020
52-wk High
€114.60
52-wk Low
€76.45

Latest Key Developments (Source: Significant Developments)

Morphosys Sees Higher 2019 Revenues On GSK Milestone Payment
Wednesday, 7 Aug 2019 

Aug 7 (Reuters) - Morphosys AG ::Financial year 2019 guidance update following GSK milestone payment: revenues in range of 65 mln to 72 mln eur (previously 43 mln to 50 mln eur) .Sees EBIT of -105 mln to -115 mln eur (previously -127 mln to -137 mln eur).Expenses for proprietary R&D remain unchanged in the range of 95 mln to 105 mln eur.Q2 revenues of 34.7 mln eur.Q2 EBIT of -5.7 mln eur.Q2 net loss of 5.9 mln eur.  Full Article

Morphosys And Vivoryon Therapeutics Enter Agreement On Small Molecule Inhibitors Of CD47-SIRP Alpha Signaling In Immuno-Oncology
Tuesday, 9 Jul 2019 

July 8 (Reuters) - Morphosys AG ::DGAP-NEWS: MORPHOSYS AND VIVORYON THERAPEUTICS ENTER AGREEMENT ON SMALL MOLECULE INHIBITORS OF CD47-SIRP ALPHA SIGNALING IN IMMUNO-ONCOLOGY.MORPHOSYS-IN EXCHANGE,CO COMMITTED TO INVESTING UP TO EUR 15 MILLION IN MINORITY STAKE IN VIVORYON AS PART OF A CAPITAL RAISE PLANNED FOR LATER THIS YEAR.MORPHOSYS -CO & VIVORYON THERAPEUTICS ENTERED DEAL UNDER WHICH CO OBTAINED EXCLUSIVE OPTION TO LICENSE VIVORYON'S SMALL MOLECULE QPCTL INHIBITORS IN FIELD OF ONCOLOGY.MORPHOSYS WILL CONDUCT PRECLINICAL VALIDATION EXPERIMENTS ON VIVORYON'S FAMILY OF QPCTL INHIBITORS.MORPHOSYS - IF CO CHOOSES TO EXERCISE OPTION, VIVORYON THERAPEUTICS WILL RECEIVE AN OPTION FEE, AND IS ELIGIBLE FOR MILESTONE PAYMENTS AND ROYALTIES.  Full Article

Morphosys Says Its Licensing Partner GSK Starts Phase 3 Otilimab Programme
Wednesday, 3 Jul 2019 

July 3 (Reuters) - MorphoSys AG ::DGAP-NEWS: MORPHOSYS'S LICENSING PARTNER GSK INITIATES PHASE 3 CLINICAL PROGRAM WITH OTILIMAB (MOR103/GSK3196165) IN RHEUMATOID ARTHRITIS; MORPHOSYS UPDATES ITS FINANCIAL GUIDANCE FOR 2019.ANNOUNCES THAT ITS LICENSING PARTNER GSK REPORTED IN A PRESS RELEASE EARLIER TODAY START OF A PHASE 3 CLINICAL DEVELOPMENT PROGRAM WITH OTILIMAB IN RHEUMATOID ARTHRITIS.  Full Article

Morphosys And I-Mab Biopharma Announce First Patient Dosed In Phase 3 Clinical Study Of Mor202/Tj202 In Multiple Myeloma
Tuesday, 30 Apr 2019 

April 29 (Reuters) - MorphoSys AG ::DGAP-NEWS: MORPHOSYS AND I-MAB BIOPHARMA ANNOUNCE FIRST PATIENT DOSED IN PHASE 3 CLINICAL STUDY OF MOR202/TJ202 IN MULTIPLE MYELOMA.  Full Article

Morphosys Announces That Its Licensee Janssen Has Expanded Clinical Development Of Guselkumab Into Familial Adenomatous Polyposis
Tuesday, 16 Apr 2019 

April 15 (Reuters) - MorphoSys AG ::IN CONNECTION WITH START OF CLINICIAL DEVELOPMENT IN FAP, MORPHOSYS RECEIVED A MILESTONE PAYMENT FROM JANSSEN.ANNOUNCES THAT ITS LICENSEE JANSSEN HAS EXPANDED CLINICAL DEVELOPMENT OF GUSELKUMAB (TREMFYA(R)) INTO FAMILIAL ADENOMATOUS POLYPOSIS.MORPHOSYS ANNOUNCES THAT ITS LICENSEE JANSSEN HAS EXPANDED CLINICAL DEVELOPMENT OF GUSELKUMAB INTO FAMILIAL ADENOMATOUS POLYPOSIS.MILESTONE PAYMENT FINANCIAL DETAILS WERE NOT DISCLOSED..  Full Article

Morphosys Says Nominates New Candidate For Supervisory Board
Thursday, 11 Apr 2019 

April 10 (Reuters) - MorphoSys AG ::DGAP-NEWS: MORPHOSYS NOMINATES NEW CANDIDATE FOR SUPERVISORY BOARD.SUPERVISORY BOARD HAS NOMINATED SHARON CURRAN AS CANDIDATE TO BE ELECTED AS NEW ADDITIONAL SUPERVISORY BOARD MEMBER AT COMPANY'S AGM.SUPERVISORY BOARD WILL PROPOSE RE-ELECTION OF KRISJA VERMEYLEN, WHOSE TERM OF OFFICE WOULD EXPIRE WITH CONCLUSION OF AGM 2019.  Full Article

MorphoSys AG FY Revenue Rose 14 Percent To 76.4 Million EUR
Thursday, 14 Mar 2019 

March 13 (Reuters) - MorphoSys AG ::FY NET LOSS -56.2 MILLION EUR VERSUS -69.8 MILLION EUR LOSS YEAR AGO.FY REVENUE ROSE 14 PERCENT TO 76.4 MILLION EUR.FY EBIT LOSS EUR 59.1 MILLION VERSUS LOSS OF EUR 67.6 MILLION IN 2017.REVENUES IN 2019 FINANCIAL YEAR ARE EXPECTED TO BE BELOW THOSE ACHIEVED IN 2018.FOR FY 2019, MORPHOSYS EXPECTS TO GENERATE GROUP REVENUES IN RANGE OF EUR 43 MILLION TO EUR 50 MILLION.EXPECTS 2019 EBIT LOSS OF EUR 127 MILLION TO EUR 137 MILLION.  Full Article

Morphosys: Licensee Janssen Receives U.S. FDA Approval For Tremfya(R) One-Press Patient-Controlled Injector For Adults With Moderate-To-Severe Plaque Psoriasis
Wednesday, 27 Feb 2019 

Feb 27 (Reuters) - MORPHOSYS AG ::ANNOUNCES THAT ITS LICENSEE JANSSEN HAS RECEIVED U.S. FDA APPROVAL FOR TREMFYA(R) ONE-PRESS PATIENT-CONTROLLED INJECTOR FOR ADULTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS.  Full Article

Morphosys Announces Settlement In Patent Lawsuit With Janssen And Genmab
Thursday, 31 Jan 2019 

Jan 31 (Reuters) - MorphoSys AG ::ANNOUNCES SETTLEMENT IN PATENT LAWSUIT WITH JANSSEN AND GENMAB.PARTIES TO DISPUTE HAVE AGREED TO DROP MUTUAL CLAIMS RELATED TO THIS LITIGATION.  Full Article

Morphosys Says Its Licensee Janssen Has Expanded Clinical Development Of Guselkumab Into Ulcerative Colitis
Friday, 18 Jan 2019 

Jan 17 (Reuters) - MorphoSys AG ::MORPHOSYS ANNOUNCES THAT ITS LICENSEE JANSSEN HAS EXPANDED CLINICAL DEVELOPMENT OF GUSELKUMAB (TREMFYA(R)) INTO ULCERATIVE COLITIS.MORPHOSYS AG- JANSSEN HAS INITIATED A PROOF-OF-CONCEPT PHASE 2A CLINICAL TRIAL IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS .MORPHOSYS IS ELIGIBLE TO CERTAIN MILESTONE PAYMENTS AND RECEIVES ROYALTIES ON NET SALES OF TREMFYA (R).  Full Article

CORRECTED-BRIEF-Morphosys Confirms Higher 2019 Revenue Guidance

* Financial year 2019 guidance, updated in July, confirmed: revenues in range of 65 mln to 72 mln eur